Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Multistate Models: Accurate and Dynamic Methods to Improve Predictions of Thrombotic Risk in Patients with Cancer
Alberto Carmona‐Bayonas, Paula Jiménez‐Fonseca, Marcelo Garrido, et al.
Thrombosis and Haemostasis (2019) Vol. 119, Iss. 11, pp. 1849-1859
Closed Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D‐Dimer analysis: A prospective study
Florian Posch, Julia Riedl, Eva‐Maria Reitter, et al.
Journal of Thrombosis and Haemostasis (2020) Vol. 18, Iss. 6, pp. 1348-1356
Open Access | Times Cited: 47
A snapshot of cancer-associated thromboembolic disease in 2018–2019: First data from the TESEO prospective registry
Alberto Carmona‐Bayonas, David Gómez, Eva Martínez de Castro, et al.
European Journal of Internal Medicine (2020) Vol. 78, pp. 41-49
Open Access | Times Cited: 34
Development, validation, and clinical utility of risk prediction models for cancer-associated venous thromboembolism: A retrospective and prospective cohort study
Shuai Jin, Dan Qin, Chong Wang, et al.
Asia-Pacific Journal of Oncology Nursing (2025), pp. 100691-100691
Open Access
Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?
Débora Contreras Toledo, Paula Jiménez‐Fonseca, Carlos López, et al.
British Journal of Cancer (2024) Vol. 130, Iss. 5, pp. 777-787
Closed Access | Times Cited: 3
Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry
Almudena Cotes Sanchís, Javier Gállego, Raquel Hernández, et al.
PLoS ONE (2020) Vol. 15, Iss. 7, pp. e0235848-e0235848
Open Access | Times Cited: 22
Dynamics of D‐dimer in non‐small cell lung cancer patients receiving radical surgery and its association with postoperative venous thromboembolism
Lihui Ke, Songping Cui, Shuo Chen, et al.
Thoracic Cancer (2020) Vol. 11, Iss. 9, pp. 2483-2492
Open Access | Times Cited: 15
Identification of Thrombosis-Related Genes in Patients with Advanced Gastric Cancer: Data from AGAMENON-SEOM Registry
David Zaragoza-Huesca, Pedro Garrido, Paula Jiménez‐Fonseca, et al.
Biomedicines (2022) Vol. 10, Iss. 1, pp. 148-148
Open Access | Times Cited: 9
Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data
Ana Fernández Montés, Alberto Carmona‐Bayonas, Paula Jiménez‐Fonseca, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 12
Causal Considerations Can Inform the Interpretation of Surprising Associations in Medical Registries
Alberto Carmona‐Bayonas, Paula Jiménez‐Fonseca, Javier Gállego, et al.
Cancer Investigation (2021) Vol. 40, Iss. 1, pp. 1-13
Closed Access | Times Cited: 12
Rationale, design and methodology of TESEO study: a registry of thrombosis and neoplasia of SEOM (Spanish Society of Medical Oncology)
José Muñoz-Langa, Paula Jiménez‐Fonseca, Alberto Carmona‐Bayonas, et al.
Clinical & Translational Oncology (2020) Vol. 23, Iss. 4, pp. 799-811
Closed Access | Times Cited: 9
Venetoclax is a potent hepsin inhibitor that reduces the metastatic and prothrombotic phenotypes of hepsin-expressing colorectal cancer cells
M.C. Rodenas, Julia Peñas-Martínez, Irene Pardo-Sánchez, et al.
Frontiers in Molecular Biosciences (2023) Vol. 10
Open Access | Times Cited: 3
Associations Between Immune-Related Venous Thromboembolism and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Huimin Li, Hong Li, Le Tang, et al.
Clinical and Applied Thrombosis/Hemostasis (2023) Vol. 29
Open Access | Times Cited: 3
External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?
Paula Jiménez‐Fonseca, Alberto Carmona‐Bayonas, Eva Martínez de Castro, et al.
Gastric Cancer (2020) Vol. 24, Iss. 2, pp. 445-456
Open Access | Times Cited: 7
External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry
Paula Jiménez‐Fonseca, Alberto Carmona‐Bayonas, Alba Martínez-Torrón, et al.
Therapeutic Advances in Medical Oncology (2021) Vol. 13
Open Access | Times Cited: 6
The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
Paula Jiménez‐Fonseca, Victoria Foy, Sophie Raby, et al.
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 2
Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry
Javier Gállego, Aránzazu Arias‐Martínez, Arturo Lecumberri, et al.
ESMO Open (2022) Vol. 7, Iss. 3, pp. 100514-100514
Open Access | Times Cited: 4
Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial
Alberto Carmona‐Bayonas, Melina Verso, Manuel Sánchez Cánovas, et al.
Thrombosis and Haemostasis (2022) Vol. 122, Iss. 10, pp. 1653-1661
Open Access | Times Cited: 3
Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry
Sena Valcárcel González, Javier Gállego, Paula Jiménez‐Fonseca, et al.
Journal of Cancer Research and Clinical Oncology (2022) Vol. 149, Iss. 7, pp. 4077-4089
Closed Access | Times Cited: 3
Pulmonary metastases and bleeding in the anticoagulated oncology patient with thrombosis: is the risk solely influenced by the location of distant disease?
Manuel Sánchez-Cánovas, Javier López Robles
European Journal of Internal Medicine (2024) Vol. 132, pp. 40-41
Closed Access
Modeling Complexity: The Case of Cancer-Related Venous Thromboembolism
Alok A. Khorana
Thrombosis and Haemostasis (2019) Vol. 119, Iss. 11, pp. 1713-1715
Open Access | Times Cited: 3
Primary Thromboprophylaxis in Children with Cancer: A Road Less Travelled
Chantal Attard, Vera Ignjatović
Thrombosis and Haemostasis (2019) Vol. 119, Iss. 12, pp. 1894-1896
Open Access | Times Cited: 3
Thrombosis and Haemostasis 2019 Editor's Choice Papers
Christian Weber, Anne Rigby, Gregory Y.H. Lip
Thrombosis and Haemostasis (2020) Vol. 120, Iss. 01, pp. 184-190
Closed Access | Times Cited: 3
TESEO, cancer-associated thrombosis registry from the Spanish Society of Medical Oncology (SEOM)
Andrés J. Muñoz Martín, Paula Jiménez‐Fonseca, Alberto Carmona‐Bayonas, et al.
Clinical & Translational Oncology (2019) Vol. 22, Iss. 8, pp. 1423-1424
Closed Access | Times Cited: 2
Decoding risk: Caravaggio's insights into risk factors for anticoagulation in cancer-associated thrombosis
Javier López Robles, Alberto Carmona‐Bayonas, Paula Jiménez‐Fonseca
European Journal of Internal Medicine (2023) Vol. 112, pp. 21-23
Closed Access
Pro-tumor and prothrombotic activities of hepsin in colorectal cancer cells and suppression by venetoclax
M.C. Rodenas, Julia Peñas-Martínez, Irene Pardo-Sánchez, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
Page 1 - Next Page

Scroll to top